Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Biosimilars dropped from FDARA

Congressional staff made no progress toward reaching consensus on biosimilars legislation in August and have dropped plans to include it in the FDA Revitalization Act (FDARA). The lightened bill, which includes reauthorization of PDUFA as well as new drug safety measures, is expected to reach President Bush's desk

Read the full 489 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers